Other Information.
+Added: During the quarter ended March 31, 2026, none of our officers (as defined in Rule 16a-1(f) under the Exchange Act) or directors adopted or terminated a “Rule 10b5-1 trading arrangements” and “non-Rule 10b5-1 trading arrangements” as those terms are defined in Item 408 of Regulation S-K.
+Added: During the quarter ended December 31, 2025, one of our officers (as defined in Rule 16a-1(f) under the Exchange Act) adopted a “Rule 10b5-1 trading arrangement” for the sale of our common stock, as set forth in the table below.
+Added: Name and Position
+Added: Adoption/ Termination Date
+Added: Rule 10b5-1 (1)
+Added: Non-Rule 10b5-1 (2)
+Added: Total Shares of Common Stock to be Sold
+Added: Expiration Date
+Added: Mark Novara, Executive Vice President and Chief Commercial Officer
+Added: December 4, 2025
+Added: March 31, 2027
+Added: (1) Contract, instruction or written plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act.
+Added: (2) “Non- Rule 10b5-1 trading arrangement” as defined in Item 408(c) of Regulation S-K under the Exchange Act.
+Added: Novara’s Rule 10b5-1 trading plan provides for the sale of 6,469 shares of our common stock, plus 10% of the Net Shares of common stock issued to Mr.
+Added: Novara upon settlement of restricted stock unit and performance stock unit awards.
+Added: For purposes of the foregoing, “Net Shares” means the number of shares of common stock issued to Mr.
+Added: Novara net of any shares surrendered to us or sold to cover withholding taxes.
+Added: The maximum number of shares that could be subject to the Rule 10b5-1 trading plan is 7,481 which represents 6,469 shares of our common stock plus 10% of the number of shares issuable upon settlement of the applicable restricted stock unit and performance stock unit awards, assuming no shares are surrendered or sold to cover withholding tax.
Incorporated by Reference Provided Herewith
3 unchanged sentences
August 3, 2023 3.1
−Removed: 3.2 Amended and Restated Bylaws of the Registrant (as amended and currently in effect).
−Removed: August 3, 2023 3.2
+Added: 3.2 Amended and Res tated Bylaws of the Registra nt (as amended and currently in effect).
+Added: December 30, 2025 3.1
+Added: 4.1 Indenture, dated as of February 27, 2026, by and between the Company and U.S.
+Added: Bank Trust Company, National Association, as Trustee.
+Added: February 27, 2026 4.1
+Added: 4.2 F orm of Global Note, representing the Company’s 0.00% Convertible Senior Notes due 2032 .
+Added: February 27, 2026 4.2
+Added: 10.1 Fo rm of Confirmation for Capped Call Transactions
+Added: February 27, 2026 10.1
31.1 Certification of John F.
19 unchanged sentences
Tandem Diabetes Care, Inc.
−Removed: November 6, 2025
President and Chief Executive Officer
1 unchanged sentence
Principal Executive Officer)
−Removed: November 6, 2025
Executive Vice President, Chief Financial Officer and Treasurer
1 unchanged sentence
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.